{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T19:30:05Z","timestamp":1771875005215,"version":"3.50.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>New treatments are required for rituximab-refractory follicular lymphoma (FL). In the present study, patients with rituximab-refractory FL received 8 weekly infusions of ofatumumab (CD20 mAb; dose 1, 300 mg and doses 2-8, 500 or 1000 mg; N = 116). The median age of these patients was 61 years, 47% had high-risk Follicular Lymphoma International Prognostic Index scores, 65% were chemotherapy-refractory, and the median number of prior therapies was 4. The overall response rate was 13% and 10% for the 500-mg and 1000-mg arms, respectively. Among 27 patients refractory to rituximab monotherapy, the overall response rate was 22%. The median progression-free survival was 5.8 months. Forty-six percent of patients demonstrated tumor reduction 3 months after therapy initiation, and the median progression-free survival for these patients was 9.1 months. The most common adverse events included infections, rash, urticaria, fatigue, and pruritus. Three patients experienced grade 3 infusion-related reactions, none of which were considered serious events. Grade 3-4 neutropenia, leukopenia, anemia, and thrombocytopenia occurred in a subset of patients. Ofatumumab was well tolerated and modestly active in this heavily pretreated, rituximab-refractory population and is therefore now being studied in less refractory FL and in combination with other agents in various B-cell neoplasms. The present study was registered at www.clinicaltrials.gov as NCT00394836.<\/jats:p>","DOI":"10.1182\/blood-2011-09-378323","type":"journal-article","created":{"date-parts":[[2012,3,5]],"date-time":"2012-03-05T20:05:46Z","timestamp":1330977946000},"page":"3698-3704","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study"],"prefix":"10.1182","volume":"119","author":[{"given":"Myron S.","family":"Czuczman","sequence":"first","affiliation":[{"name":"Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Delwail","sequence":"additional","affiliation":[{"name":"Les Centres d'Investigation Clinique 0802 Inserm, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Centre Hospitalier Universitaire Montpellier Unit\u00e9 Mixte de Recherche 5235, Montpellier, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazimierz","family":"Kuliczkowski","sequence":"additional","affiliation":[{"name":"Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[{"name":"University of Iowa, Iowa City, IA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[{"name":"University of California, Los Angeles, Los Angeles, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Radford","sequence":"additional","affiliation":[{"name":"Christie National Health Service Foundation Trust and The University of Manchester, Manchester, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Medical University of Gda\u0144sk, Gda\u0144sk, Poland;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Gallop-Evans","sequence":"additional","affiliation":[{"name":"Velindre Hospital, Cardiff, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine G.","family":"DiRienzo","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Goldstein","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Gupta","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxanne C.","family":"Jewell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Research Triangle Park, NC;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Lin","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Collegeville, PA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen","family":"Lisby","sequence":"additional","affiliation":[{"name":"Genmab, Copenhagen, Denmark; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schultz","sequence":"additional","affiliation":[{"name":"Genmab, Copenhagen, Denmark; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte A.","family":"Russell","sequence":"additional","affiliation":[{"name":"Genmab, Copenhagen, Denmark; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Hagenbeek","sequence":"additional","affiliation":[{"name":"Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"17","key":"2019111809213929400_B1","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of retreatment.","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111809213929400_B2","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","article-title":"Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.","volume":"103","author":"Ghielmini","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2019111809213929400_B3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","article-title":"Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network.","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111809213929400_B4","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111809213929400_B5","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/cncr.24714","article-title":"Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.","volume":"116","author":"Kahl","year":"2010","journal-title":"Cancer"},{"key":"2019111809213929400_B6","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1053\/j.seminoncol.2005.01.014","article-title":"Development of 131I-tositumomab.","volume":"32","author":"Lewington","year":"2005","journal-title":"Semin Oncol"},{"issue":"4","key":"2019111809213929400_B7","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111809213929400_B8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2000.18.6.1316","article-title":"Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed\/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.","volume":"18","author":"Vose","year":"2000","journal-title":"J Clin Oncol"},{"issue":"15","key":"2019111809213929400_B9","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111809213929400_B10","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1200\/JCO.2007.12.5070","article-title":"Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.","volume":"26","author":"Friedberg","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111809213929400_B11","first-page":"1507","article-title":"Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.","volume":"43","author":"Juweid","year":"2002","journal-title":"J Nucl Med"},{"key":"2019111809213929400_B12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/asheducation-2005.1.335","article-title":"Targeting CD20 in follicular NHL: novel anti-CD20 therapies, antibody engineering, and the use of radioimmunoconjugates.","volume":"2005","author":"Leonard","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2019111809213929400_B13","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study.","volume":"27","author":"Friedberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111809213929400_B14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"issue":"20","key":"2019111809213929400_B15","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma.","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111809213929400_B16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/asheducation-2007.1.233","article-title":"Monoclonal antibodies for B-cell lymphomas: rituximab and beyond.","volume":"2007","author":"Bello","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2019111809213929400_B17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111809213929400_B18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"issue":"12","key":"2019111809213929400_B19","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"issue":"21","key":"2019111809213929400_B20","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","article-title":"In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.","volume":"67","author":"Macor","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"2019111809213929400_B21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"issue":"3","key":"2019111809213929400_B22","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"issue":"13","key":"2019111809213929400_B23","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-06-0066","article-title":"Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.","volume":"12","author":"van Meerten","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111809213929400_B24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2019111809213929400_B25","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","article-title":"Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.","volume":"113","author":"Dayd\u00e9","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111809213929400_B26","doi-asserted-by":"crossref","first-page":"822","DOI":"10.4049\/jimmunol.181.1.822","article-title":"Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.","volume":"181","author":"Beum","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"2019111809213929400_B27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.4049\/jimmunol.0900632","article-title":"Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.","volume":"183","author":"Pawluczkowycz","year":"2009","journal-title":"J Immunol"},{"issue":"6","key":"2019111809213929400_B28","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111809213929400_B29","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1182\/blood-2007-10-117671","article-title":"First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1\/2 trial.","volume":"111","author":"Hagenbeek","year":"2008","journal-title":"Blood"},{"key":"2019111809213929400_B30","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours","author":"Jaffe","year":"2001"},{"issue":"4","key":"2019111809213929400_B31","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, NCI Sponsored International Working Group.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111809213929400_B32","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.","volume":"172","author":"Kennedy","year":"2004","journal-title":"J Immunol"},{"issue":"16","key":"2019111809213929400_B33","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","article-title":"Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab.","volume":"113","author":"Hilchey","year":"2009","journal-title":"Blood"},{"key":"2019111809213929400_B34","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.1200\/jco.2010.28.15_suppl.8095","article-title":"Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma [abstract].","volume":"28","author":"Barth","year":"2010","journal-title":"J Clin Oncol"},{"key":"2019111809213929400_B35","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.1200\/jco.2010.28.15_suppl.8042","article-title":"Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL) [abstract].","volume":"28","author":"Czuczman","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809213929400_B36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111809213929400_B37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111809213929400_B38","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111809213929400_B39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1023\/A:1008332713631","article-title":"Response criteria for NHL: importance of \u2018normal\u2019 lymph node size and correlations with response rates.","volume":"11","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Ann Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/16\/3698\/1475735\/zh801612003698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/16\/3698\/1475735\/zh801612003698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T01:15:20Z","timestamp":1713662120000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/16\/3698\/29909\/Ofatumumab-monotherapy-in-rituximabrefractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,19]]},"references-count":39,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,4,19]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-09-378323","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,19]]}}}